Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

Abstract The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST‐2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we pres...

Full description

Bibliographic Details
Main Authors: Naveen Pemmaraju, Claire Harrison, Vikas Gupta, Srdan Verstovsek, Bart Scott, Stephen T. Oh, Francesca Palandri, Haifa Kathrin Al‐Ali, Marta Sobas, Mary Frances McMullin, Ruben Mesa, Sarah Buckley, Karisse Roman‐Torres, Alessandro Vannucchi, Abdulraheem Yacoub
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:eJHaem
Subjects:
myelofibrosis
myeloproliferative neoplasms
pacritinib
safety
Online Access:https://doi.org/10.1002/jha2.591

Internet

https://doi.org/10.1002/jha2.591

Similar Items